STRO
Sutro Biopharma
NASDAQ: STRO · HEALTHCARE · BIOTECHNOLOGY
$40.91
-9.03% today
Updated 2026-06-05
Market cap
$432.32M
P/E ratio
—
P/S ratio
4.34x
EPS (TTM)
$-16.35
Dividend yield
—
52W range
$7 – $44
Volume
0.3M
Sutro Biopharma (STRO) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$40.91
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$49.91
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.2B | $0.1B | $0.1B | $0.1B | $0.1B | $0.2B | $0.2B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 19.12% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -154.20%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.